Figure 4.

Schematic diagram indicating a new type of precision medicine for prostate diseases. (A) In symptomatic BPH and in organ-confined prostate cancer where PAGE4 is upregulated, inhibiting PAGE4 using small molecule inhibitors may be a novel therapeutic strategy to treat these diseases. (B) Reinstituting PAGE4’s sustained expression either by intermittent ADT (IAD) or protein expression in metastatic prostate cancer, where it is downregulated, is likely to subvert or attenuate the emergence of CRPC. OC, organ-confined; Met, metastatic; AD, androgen-dependent; AI, androgen-independent.